Each year at the J.P. Morgan Healthcare Conference, pharma CEOs are tasked with assuring and convincing investors that they’ve positioned their companies to overcome expected challenges. Monday, three Big Pharma leaders took center stage and addressed concerns about future patent
read moreWhat connects a broken windshield, a raccoon infestation and Peyronie’s disease? According to Endo, all three challenges are examples of when people benefit from speaking up and getting recommendations from trusted sources. More: Endo delivers more straight talk in fresh
read moreAgainst the backdrop of poor sales for the company’s COVID-19 shot Spikevax and its recently approved RSV prophylactic mRESVIA, Moderna is “accelerating and expanding” its prior efficiency and prioritization efforts. The company plans to hive off roughly $1 billion from
read more
Survey finds AI to enhance productivity and cut costs in the next 12 months More: AI set to revolutionise pharmaceutical R&D says GlobalData Source: News
read more
Companies aim to provide new treatments for inflammatory conditions More: Gilead and LEO Pharma partner to develop oral STAT6 program Source: News
read moreJohnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based
read more© 1994 - 2026 B.M. Pharmaceuticals